Combining amylin agonist with tirzepatide leads to further weight loss in type 2 diabetes
Eli Lilly's phase 2 trial showed that combining eloralintide (an investigational amylin agonist) with tirzepatide (Mounjaro/Zepbound) led to significant weight loss (up to 23.3%) and HbA1c reduction (up to 2.9 percentage points) in adults with type 2 diabetes. The combination therapy outperformed tirzepatide alone. Lilly plans a phase 3 trial with a co-formulated injection.
How this was made
The 30-second read
Why it matters
The data suggest a significant therapeutic advantage, likely prompting analyst upgrades and short‑term buying interest.
Market read
First public disclosure of compelling combination trial results, positioning Lilly as a leader in metabolic disease innovation.
What to watch
Regulatory pathway for combination products may be more complex, affecting timeline and market expectations.
Background
The article reports new phase 2 data on Eli Lilly's investigational amylin agonist eloralintide combined with tirzepatide, presented at the EASD meeting.
Ticker impact
Eli Lilly disclosed phase 2 trial results showing combined eloralintide and tirzepatide achieved up to 23.3% weight loss and ~2.9% HbA1c reduction in type 2 diabetes patients.
upward pressure as market prices in the strong efficacy results and upcoming phase 3 plans.
First disclosure of robust weight‑loss and glycemic outcomes; comparable data have previously driven share gains for Lilly.
Market effects
Strengthens the obesity‑diabetes therapeutic segment, potentially boosting peers developing combination therapies.
U.S. biotech sector may see modest gains as investors reassess pipeline valuations.
Highlights growing interest in multi‑mechanism metabolic treatments worldwide.
Counterpoint
If phase 3 co‑formulation delays or safety concerns emerge, the initial hype could reverse.
Key entities
- CompanyEli Lilly
Pharmaceutical company developing eloralintide and tirzepatide.
